Crinetics Pharmaceuticals, Inc. — Director's Dealing 2019

Dec 19, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2019-12-16

Reporting Person: Fust Matthew K (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-16	Common Stock	M	3500	$1.91	Acquired	16036	Direct
2019-12-16	Common Stock	S	3500	$22.50	Disposed	12536	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-16	Non-qualified stock option (Right to Buy)	$1.91	M	3500	Disposed	2028-03-16	Common stock (3500)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date.

F2: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.